Publications

Latest publication 03/23/2016

Targeting protein homeostasis in sporadic inclusion body myositis

Sporadic inclusion body myositis (sIBM) is the commonest severe myopathy in patients more than 50 years of age. Previous therapeutic trials have...

Array
(
    [id_prestablog_news] => 852
    [id_shop] => 1
    [date] => 2016-03-23 00:00:00
    [date_modification] => 2024-02-09 14:15:12
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [prim_key] => 1667
    [id_lang] => 1
    [title] => Targeting protein homeostasis in sporadic inclusion body myositis
    [paragraph] => Targeting protein homeostasis in sporadic inclusion body myositis
    [content] => 

Authors
Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J et al.


Lab
Medical Research Council (MRC) Centre for Neuromuscular Diseases, University College London (UCL) Institute of Neurology, Queen Square, London WC1N 3BG, UK

Journal
Sci Transl Med.

Abstract
Sporadic inclusion body myositis (sIBM) is the commonest severe myopathy in patients more than 50 years of age. Previous therapeutic trials have targeted the inflammatory features of sIBM but all have failed. Because protein dyshomeostasis may also play a role in sIBM, we tested the effects of targeting this feature of the disease. Using rat myoblast cultures, we found that up-regulation of the heat shock response with arimoclomol reduced key pathological markers of sIBM in vitro. Furthermore, in mutant valosin-containing protein (VCP) mice, which develop an inclusion body myopathy, treatment with arimoclomol ameliorated disease pathology and improved muscle function. We therefore evaluated arimoclomol in an investigator-led, randomized, double-blind, placebo-controlled, proof-of-concept trial in sIBM patients and showed that arimoclomol was safe and well tolerated. Although arimoclomol improved some IBM-like pathology in the mutant VCP mouse, we did not see statistically significant evidence of efficacy in the proof-of-concept patient trial.

[meta_description] => [meta_keywords] => http://www.ncbi.nlm.nih.gov/pubmed/27009270 [meta_title] => [link_rewrite] => targeting-protein-homeostasis-in-sporadic-inclusion-body-myositis [actif_langue] => 1 [read] => 847 [count_comments] => 0 [id] => 852 [categories] => Array ( [26] => Array ( [id_prestablog_categorie] => 26 [title] => Miscellaneous research domains [link_rewrite] => Miscellaneous-research-domains ) [2] => Array ( [id_prestablog_categorie] => 2 [title] => Publications [link_rewrite] => publications ) ) [authors] => [paragraph_crop] => Targeting protein homeostasis in sporadic inclusion body myositis [link_for_unique] => 1 [products_liaison] => Array ( [48] => Array ( [name] => Grip strength test [description_short] =>

An easy way to objectively quantify the muscular strength of mice and rats, and to assess the effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration. It is widely used in conjunction with the ROTAROD motor coordination test: a normally coordinated rodent will show a decreased latency to fall off the rotating rod if its muscular strength is low. The Grip Strength Test is a must for your research on activity, motor control & coordination, and is particularly well suited for studies on Parkinson's & Huntington's disease.

New features GS4 - 2023: Color display with permanent backlight screen for easier reading, reset by footswitch, Improved battery time, Larger data memory of 500 values, Animal counter, USB port (charging/data transfer)

forrats.pngformice.png

[thumb] => [img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg [image_presente] => 1 [link] => https://bioseb.com/en/activity-motor-control-coordination/48-grip-strength-test.html ) ) ) 1
Read more

Filters

Applications

Dates

<< 1 ... 91 92 93 94 95 >>